AuNPs can successfully deliver β-catenin-BCL9 interaction-disrupting peptides into cancer cells to inhibit Wnt/β-catenin signaling and tumor growth with favorable biosafety and biocompatibility [298,299]. This evidence concerns the gene BCL9 and cancer.